Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A synthetic 29-residue C-terminally amidated peptide corresponding to the N-terminal fragment of a 44-residue hypothalamic peptide.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (29 residues, C-terminal amide)
Molecular formula
C149H246N44O42S
Molecular weight
~3,358 g/mol
CAS number
86168-78-7
Amino acids
29
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Modification
C-terminal amidation; sequence corresponds to residues 1-29 of human GHRH (the N-terminal fragment that retains intrinsic activity).
A synthetic 29-residue C-terminally amidated peptide corresponding to the N-terminal fragment (residues 1-29) of a 44-residue hypothalamic peptide - the minimal segment that retains the intrinsic structural activity of the longer parent. Solution NMR in a membrane-mimetic solvent describes substantial alpha-helical character, and cryo-EM of the peptide bound to its class B1 (secretin-like) G-protein-coupled receptor complex resolves a continuous alpha-helical conformation contacting the receptor extracellular domain, extracellular loops, and transmembrane helices. Binding is described by a two-domain ('two-step') model in which the peptide engages both the receptor extracellular domain and its transmembrane core. As a small unmodified peptide it carries a single oxidation-sensitive methionine and is characterized by rapid circulatory clearance, distinguishing it from chemically stabilized analogs bearing acyl or amino-acid-substitution modifications.
Lyophilized
20°C (-80°C long term)
powder protected from light, typically stable many months desiccated.
Avoid freeze-thaw; aliquot; protect from light and moisture. Contains an oxidation-sensitive methionine.
Reviews
Granata R, et al. (2025). Nat Rev Endocrinol
Montero-Hidalgo AJ, et al. (2025). Rev Endocr Metab Disord
Walker RF. (2006). Clin Interv Aging
Reviews
Lin-Su K, Wajnrajch MP. (2002). Rev Endocr Metab Disord
Prakash A, Goa KL. (1999). BioDrugs
Clinical
Baker LD, et al. (2012). Arch Neurol
Khorram O, et al. (1997). J Clin Endocrinol Metab
Vittone J, et al. (1997). Metabolism
Thorner M, et al. (1996). J Clin Endocrinol Metab
Corpas E, et al. (1992). J Clin Endocrinol Metab
ClinicalTrials.gov. ClinicalTrials.gov
Primary research
Zhou F, et al. (2020). Nat Commun
Kanashiro-Takeuchi RM, et al. (2012). Proc Natl Acad Sci USA
Kanashiro-Takeuchi RM, et al. (2010). Proc Natl Acad Sci USA
Godfrey P, et al. (1993). Nat Genet
Mayo KE. (1992). Mol Endocrinol
Theriault Y, et al. (1988). Biopolymers
Ling N, et al. (1984). Proc Natl Acad Sci USA
Rivier J, et al. (1982). Nature
Guillemin R, et al. (1982). Science
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| SermorelinThis page | Synthetic peptide (29 residues, C-terminal amide) | ~3,358 g/mol | 86168-78-7 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods